Next Article in Journal
Imaging Techniques for the Study of Fibrosis in Atrial Fibrillation Ablation: From Molecular Mechanisms to Therapeutical Perspectives
Next Article in Special Issue
The Value of Cardiac Magnetic Resonance Imaging in Identification of Rare Diseases Mimicking Hypertrophic Cardiomyopathy
Previous Article in Journal
Screening Pregnant Women for Bacterial Vaginosis Using a Point-of-Care Test: A Prospective Validation Study
 
 
Review

Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy

1
Department of Cardiology, Clinic Cardiovascular Institute, Hospital Clinic de Barcelona, 08036 Barcelona, Spain
2
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain
3
Interventional Cardiology Unit, Policlinic G. Martino, University of Messina, 98124 Messina, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Gianluca Di Bella and Yuchi Han
J. Clin. Med. 2021, 10(11), 2276; https://doi.org/10.3390/jcm10112276
Received: 13 April 2021 / Revised: 13 May 2021 / Accepted: 19 May 2021 / Published: 24 May 2021
Hypertrophic cardiomyopathy (HCM) can cause symptoms due to the obstruction of the left ventricle outflow tract (LVOT). Although pharmacological therapy is the first step for treating this condition, many patients do not fully respond to the treatment, and an invasive approach is required to manage symptoms. Septal reduction therapies include septal myectomy (SM) and alcohol septal ablation (ASA). ASA consists of a selective infusion of high-grade alcohol into a septal branch supplying the basal interventricular septum to create an iatrogenic infarction with the aim of reducing LVOT obstruction. Currently, SM and ASA have the same level of indication; however, ASA is normally reserved for patients of advanced age, with comorbidities or when the surgical approach is not feasible. Recent data suggests that there are no differences in short- and long-term all-cause mortality, cardiovascular mortality and sudden cardiac death between ASA and SM. Despite the greater experience and refinement of the technique gained in recent years, the most common complication continues to be complete atrio-ventricular block, requiring a permanent pacemaker. Septal reduction therapies should be performed in experienced centres with comprehensive programs. View Full-Text
Keywords: hypertrophic obstructive cardiomyopathy; alcohol septal ablation; septal myectomy hypertrophic obstructive cardiomyopathy; alcohol septal ablation; septal myectomy
Show Figures

Figure 1

MDPI and ACS Style

Arévalos, V.; Rodríguez-Arias, J.J.; Brugaletta, S.; Micari, A.; Costa, F.; Freixa, X.; Masotti, M.; Sabaté, M.; Regueiro, A. Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy. J. Clin. Med. 2021, 10, 2276. https://doi.org/10.3390/jcm10112276

AMA Style

Arévalos V, Rodríguez-Arias JJ, Brugaletta S, Micari A, Costa F, Freixa X, Masotti M, Sabaté M, Regueiro A. Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy. Journal of Clinical Medicine. 2021; 10(11):2276. https://doi.org/10.3390/jcm10112276

Chicago/Turabian Style

Arévalos, Victor, Juan José Rodríguez-Arias, Salvatore Brugaletta, Antonio Micari, Francesco Costa, Xavier Freixa, Mónica Masotti, Manel Sabaté, and Ander Regueiro. 2021. "Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy" Journal of Clinical Medicine 10, no. 11: 2276. https://doi.org/10.3390/jcm10112276

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop